{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005262","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.387692+00:00","generated_at":"2026-05-17T15:11:00.783673+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Harvard Bioscience Reports Q2 2025 Revenue of $20.5M, Net Loss of $2.3M, and Credit Amendment","bullets":["Q2 2025 revenue of $20.5M vs $23.1M in Q2 2024; gross margin 56.4% vs 57.2%.","Net loss improved to ($2.3M) from ($2.9M); adjusted EBITDA rose to $1.5M from $1.3M.","Cash from operations was $2.8M, compared to ($0.8M) in Q2 2024.","Credit agreement amended waiving defaults; new refinance deadline set for December 5, 2025.","Q3 2025 revenue guidance $19M-$21M with gross margin 56%-58%."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005262","json":"https://secwatch.observer/filing/0001171843-25-005262.json","markdown":"https://secwatch.observer/filing/0001171843-25-005262.md","text":"https://secwatch.observer/filing/0001171843-25-005262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325005262/0001171843-25-005262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325005262/f8k_080525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T15:11:00.783673+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}